. 2023 Dec 26;7(24):7581-7584.

doi: 10.1182/bloodadvances.2023011428.

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Yuan Jian¹, Long Chang², Ming-Xia Shi³, Ying Sun⁴, Xiao-Xia Chu⁵, Hua Xue⁶, Wen-Rong Huang⁷, Xu-Liang Shen⁸, Jie Ma⁹, Guo-Rong Jia¹⁰, Ya-Qing Feng¹¹, Zhen-Fang Xi¹², Yan-Hong Zhao¹³, Yan-Ping Ma¹⁴, Jing Xiao¹⁵, Guang-Yu Ma¹⁶, Qing-Ming Wang¹⁷, Li Bao¹⁸, Yu-Jun Dong¹⁹, He-Bing Zhou²⁰, Chun-Yan Sun²¹, Guo-Hong Su²², Yan Yan²³, Sai-Yin Qimuge²⁴, Li-Ping Su²⁵, Jing-Nan Sun²⁶, Wei-Wei Tian²⁷, Xiu-Li Sun²⁸, Hong-Mei Jing²⁹, Da Gao³⁰, Wen-Ming Chen¹, Jian Li², Wen Gao¹

Affiliations

¹ Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
² Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
³ Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China.
⁴ Department of Hematology, Chifeng Municipal Hospital, Chifeng, China.
⁵ Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao, China.
⁶ Department of Hematology, Affiliated Hospital of Hebei University, Baoding, China.
⁷ Department of Hematology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, China.
⁸ Department of Hematology, Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China.
⁹ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
¹⁰ Department of Hematology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China.
¹¹ Department of Hematology, The Third People's Hospital Of Datong, Datong, China.
¹² Department of Hematology, Linfen People's Hospital, Linfen, China.
¹³ Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
¹⁴ Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
¹⁵ Department of Hematology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China.
¹⁶ Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
¹⁷ Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
¹⁸ Department of Hematology, Beijing Jishuitan Hospital, Beijing, China.
¹⁹ Department of Hematology, Peking University First Hospital, Beijing, China.
²⁰ Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
²¹ Institution of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²² The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou, China.
²³ Department of Hematology, Bayannur Hospital, Bayannur, China.
²⁴ Department of Hematology, Ordos Central Hospital, Ordos, China.
²⁵ Department of Hematology, Shanxi Cancer Hospital, Taiyuan, China.
²⁶ Department of Oncology, The First Hospital of Jilin University, Changchun, China.
²⁷ Department of Hematology, Shanxi Bethune Hospital, Taiyuan, China.
²⁸ Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
²⁹ Department of Hematology, Peking University Third Hospital, Beijing, China.
³⁰ Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

PMID: 37922425
PMCID: PMC10733092
DOI: 10.1182/bloodadvances.2023011428

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Yuan Jian et al. Blood Adv. 2023.

. 2023 Dec 26;7(24):7581-7584.

doi: 10.1182/bloodadvances.2023011428.

Authors

Affiliations

¹ Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
² Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
³ Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China.
⁴ Department of Hematology, Chifeng Municipal Hospital, Chifeng, China.
⁵ Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao, China.
⁶ Department of Hematology, Affiliated Hospital of Hebei University, Baoding, China.
⁷ Department of Hematology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, China.
⁸ Department of Hematology, Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China.
⁹ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
¹⁰ Department of Hematology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China.
¹¹ Department of Hematology, The Third People's Hospital Of Datong, Datong, China.
¹² Department of Hematology, Linfen People's Hospital, Linfen, China.
¹³ Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
¹⁴ Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
¹⁵ Department of Hematology, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China.
¹⁶ Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
¹⁷ Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
¹⁸ Department of Hematology, Beijing Jishuitan Hospital, Beijing, China.
¹⁹ Department of Hematology, Peking University First Hospital, Beijing, China.
²⁰ Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
²¹ Institution of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
²² The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou, China.
²³ Department of Hematology, Bayannur Hospital, Bayannur, China.
²⁴ Department of Hematology, Ordos Central Hospital, Ordos, China.
²⁵ Department of Hematology, Shanxi Cancer Hospital, Taiyuan, China.
²⁶ Department of Oncology, The First Hospital of Jilin University, Changchun, China.
²⁷ Department of Hematology, Shanxi Bethune Hospital, Taiyuan, China.
²⁸ Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
²⁹ Department of Hematology, Peking University Third Hospital, Beijing, China.
³⁰ Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

PMID: 37922425
PMCID: PMC10733092
DOI: 10.1182/bloodadvances.2023011428

Erratum in

Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584.
[No authors listed] [No authors listed] Blood Adv. 2024 Apr 23;8(8):1991. doi: 10.1182/bloodadvances.2024013036. Blood Adv. 2024. PMID: 38619856 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

**Figure 1.**
**Survival of patients with NDMM with RI receiving PVD regimen.** (A) PFS in all 61 patients who received PVD therapy. (B) OS in all 61 patients who received PVD therapy. PFS, progression-free survival.

See this image and copyright information in PMC

References

1. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337–341. - PubMed
1. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200. - PubMed
1. Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13(1):46. - PMC - PubMed
1. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423–429. - PubMed
1. Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Affiliations

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment

Authors

Affiliations

Erratum in

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Erratum in

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical